The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | T-DXd combinations in HER2+ esophageal and gastric cancers in the DESTINY-Gastric03 trial
Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, gives an overview of the Phase III DESTINY-Gastric03 (NCT04379596) trial, which assessed trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients with HER2-positive esophageal, gastric, or gastroesophageal junction adenocarcinoma (GEJA). The study examines the efficacy of T-DXd in combination with fluoropyrimidine and pembrolizumab in first-line settings. Results indicate durable clinical benefits, particularly in patients receiving higher doses. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
